What is Yarrow Bioscience, Inc.'s earnings per share (EPS)?

Yarrow Bioscience, Inc. (YARW) reported diluted earnings per share of -$0.62 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Yarrow Bioscience, Inc. (YARW) Financials

YARW

FY2025 annual

Revenue $570K +13.8% YoY

Net Income -$26.5M +33.5% YoY

EPS (Diluted) -$0.62 YoY not available

Free Cash Flow -$33.1M +2.8% YoY

Market Cap $75.6M as of Sep 21, 2026

Price / Sales 133x on $570K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 3.4x on $22.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the YARW SEC filings page.

Yarrow Bioscience, Inc. (YARW) reported $570K in revenue for fiscal year 2025, up 13.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI YARW FY2025 2026-08-29

Yarrow remains a development-stage business whose research spending drives operating losses, while investing inflows shape reported cash resources.

FY2025 operating cash flow was -$33.1M, almost identical to free cash flow of -$33.1M, despite no reported capital expenditures; the deficit therefore reflects the operating program rather than a heavy fixed-asset build. A $37.4M investing inflow more than offset that operating outflow, with financing nearly flat, so the period’s cash resources were supported by investing activity rather than internal cash generation.

Revenue rose 13.8% in FY2025 while R&D fell 37.8%; SG&A also declined. Operating loss narrowed 31.8%, indicating cost reduction—not a demonstrated scale effect—did most of the work while revenue stayed below $1M.

No reported long-term debt and a 12.5x current ratio indicate low conventional leverage, but that does not describe self-funding capacity. Assets and equity both declined in the latest year, while reported liquidity equaled 10.5 months of annual operating outflow; the contrast separates balance-sheet liquidity from recurring cash generation.

Financial Health Signals

Financial health score not available

Yarrow Bioscience, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-18.38

Yarrow Bioscience, Inc. scores -18.38, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($75.6M) relative to total liabilities ($2.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Yarrow Bioscience, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Yarrow Bioscience, Inc. reported a net loss of $26.5M while operations used $33.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$97K

YoY+40.6%

QoQ+12.8%

Yarrow Bioscience, Inc. generated $97K in revenue in Q2 2026. This represents an increase of 40.6% from the same quarter a year earlier. Against the prior quarter it is up 12.8%.

EBITDA

-$3.1M

YoY+58.9%

QoQ+18.7%

Yarrow Bioscience, Inc.'s EBITDA was -$3.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 58.9% from the same quarter a year earlier. Against the prior quarter it is up 18.7%.

Net Income

-$3.0M

YoY+47.7%

QoQ+16.1%

Yarrow Bioscience, Inc. reported -$3.0M in net income in Q2 2026. This represents an increase of 47.7% from the same quarter a year earlier. Against the prior quarter it is up 16.1%.

EPS (Diluted)

-$3.51

Yarrow Bioscience, Inc. earned -$3.51 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Cash & Debt

$22.9M

YoY+4.0%

QoQ-6.9%

5Y CAGR-28.0%

Yarrow Bioscience, Inc. held $22.9M in cash against $0 in long-term debt as of Q2 2026.

Shares Outstanding

5Y CAGR-44.6%

Yarrow Bioscience, Inc. had 3M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-13.6%

YoY+1.2pp

QoQ+0.9pp

Yarrow Bioscience, Inc.'s ROE was -13.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$788K

YoY-83.9%

QoQ-3.5%

Yarrow Bioscience, Inc. invested $788K in research and development in Q2 2026. This represents a decrease of 83.9% from the same quarter a year earlier. Against the prior quarter it is down 3.5%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

YARW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

YARW quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	$570K+13.8%	$501K+18.2%	$424K-11.1%	$477K-48.8%	$931K-95.6%	$21.0M+4638.8%	$443K-87.7%	$3.6M-21.5%	$4.6M+579.8%	$674K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$3.3M+140.5%	$1.4M	$0	$0	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	-$2.4M-112.3%	$19.6M+4324.6%	$443K-87.7%	$3.6M	N/A	N/A	N/A
R&D Expenses	$19.2M-37.8%	$30.9M+89.8%	$16.3M-11.3%	$18.4M-5.9%	$19.5M-55.1%	$43.5M-15.0%	$51.2M-20.6%	$64.5M+122.3%	$29.0M+157.7%	$11.3M+285.3%	$2.9M
SG&A Expenses	$11.1M-16.0%	$13.2M-1.4%	$13.4M-18.4%	$16.4M-19.3%	$20.3M-77.3%	$89.5M+98.5%	$45.1M+221.9%	$14.0M+171.1%	$5.2M+37.8%	$3.8M+122.3%	$1.7M
Operating Income	-$29.7M+31.8%	-$43.6M-49.1%	-$29.3M+14.7%	-$34.3M+11.9%	-$38.9M+84.6%	-$252.5M-163.4%	-$95.9M-28.0%	-$74.9M-153.1%	-$29.6M-106.5%	-$14.3M-211.0%	-$4.6M
EBITDA	-$29.7M+31.9%	-$43.6M-49.1%	-$29.3M+14.5%	-$34.2M+11.8%	-$38.8M+84.6%	-$252.2M-164.0%	-$95.5M-28.1%	-$74.6M	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	$0-100.0%	$5.6M+27.8%	$4.4M+376.7%	$921K	$0	N/A	N/A	N/A
Income Tax	$4K0.0%	$4K	$0-100.0%	$13K+102.9%	-$448K-73.6%	-$258K-46.6%	-$176K-183.0%	$212K	$0	N/A	N/A
Net Income	-$26.5M+33.5%	-$39.8M-40.0%	-$28.5M-22.6%	-$23.2M+68.3%	-$73.3M+71.3%	-$255.6M-168.5%	-$95.2M-28.3%	-$74.2M-155.1%	-$29.1M-106.7%	-$14.1M-205.3%	-$4.6M
EPS (Basic)	-$0.62+33.3%	-$0.93+66.5%	-$2.78+61.8%	-$7.28+71.6%	-$25.64-425.4%	$7.88	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.62	-$0.93	-$2.78	-$7.28	-$25.64-425.4%	$7.88	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	43M	43M	10M	3M	3M-91.2%	32M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	$97K+40.6%	$86K-57.4%	N/A	$69K-65.2%	$202K+106.1%	$84K+10.5%	$121K+6.1%	$198K+46.7%
R&D Expenses	$788K-83.9%	$817K-86.7%	N/A	$4.9M-33.2%	$6.1M+65.2%	$9.7M+220.5%	$10.2M+208.9%	$7.3M+1.0%
SG&A Expenses	$2.4M-11.7%	$3.1M-5.8%	N/A	$2.7M-17.0%	$3.3M-13.1%	$3.2M-18.4%	$3.0M-2.2%	$3.3M+2.1%
Operating Income	-$3.1M+58.9%	-$3.8M+58.5%	N/A	-$7.5M+27.5%	-$9.2M-24.6%	-$12.8M-86.9%	-$13.1M-110.0%	-$10.4M-0.8%
EBITDA	-$3.1M+58.9%	-$3.8M+58.5%	N/A	-$7.5M+27.6%	-$9.2M-24.5%	N/A	N/A	-$10.4M-0.8%
Income Tax	$0	$0	N/A	$0	$0	$4K	$0	$0
Net Income	-$3.0M+47.7%	-$3.6M+58.4%	N/A	-$5.8M+38.8%	-$8.6M-37.8%	-$12.0M-94.3%	-$12.2M-84.6%	-$9.4M+6.5%
EPS (Basic)	-$3.51+47.8%	-$0.08+60.0%	N/A	-$6.73-2959.1%	-$0.20-33.3%	-$0.28-106.9%	-$0.29+85.6%	-$0.22+92.9%
EPS (Diluted)	-$3.51	-$0.08	N/A	-$6.73	-$0.20-33.3%	-$0.28-106.9%	-$0.29	-$0.22
Diluted Shares (Avg)	858,000	42,768	N/A	855,000	42,673-99.9%	N/A	43M	43M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

YARW Balance Sheet

YARW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$30.2M-54.9%	$66.9M-31.5%	$97.7M+139.7%	$40.8M-39.2%	$67.0M-28.5%	$93.7M+15.5%	$81.2M-42.0%	$139.9M+109.3%	$66.9M+59.0%	$42.1M	N/A
Current Assets	$30.0M-53.4%	$64.4M-32.9%	$96.0M+150.7%	$38.3M-39.4%	$63.2M-27.6%	$87.3M+14.2%	$76.4M-45.2%	$139.5M+118.4%	$63.9M+102.5%	$31.5M	N/A
Cash & Equivalents	$24.0M+20.6%	$19.9M-34.9%	$30.6M-0.9%	$30.9M-26.8%	$42.3M-26.6%	$57.6M+31.5%	$43.8M+57.0%	$27.9M+173.1%	$10.2M+153.4%	$4.0M-90.8%	$43.8M
Short-Term Investments	$5.0M-88.0%	$41.6M-33.6%	$62.6M	$0	$0-100.0%	$1.0M-93.8%	$16.7M-80.8%	$86.7M+76.0%	$49.3M+83.4%	$26.9M	$0
Inventory	N/A	N/A	N/A	N/A	$7.3M-1.5%	$7.4M+446.0%	$1.4M	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$173K-97.7%	$7.6M-52.1%	$15.8M+11617.8%	$135K	N/A	$786K	$0	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$3.0M-71.4%	$10.4M	$0
Total Liabilities	$2.4M-83.8%	$14.8M+65.6%	$8.9M-4.2%	$9.3M-49.2%	$18.4M-67.3%	$56.2M-11.5%	$63.6M+33.2%	$47.7M+227.6%	$14.6M-79.6%	$71.5M	N/A
Current Liabilities	$2.4M-83.8%	$14.8M+96.6%	$7.5M-19.3%	$9.3M-49.2%	$18.4M-15.4%	$21.8M-25.8%	$29.3M+207.3%	$9.5M+22.1%	$7.8M+100.3%	$3.9M	N/A
Non-Current Liabilities	$0	$0-100.0%	$1.4M	$0	$0-100.0%	$34.5M+0.7%	$34.3M-10.3%	$38.2M+465.4%	$6.8M-90.0%	$67.6M	N/A
Long-Term Debt	$0	$0	$0	$0	$0-100.0%	$33.2M+1.4%	$32.7M	N/A	N/A	N/A	N/A
Total Equity	$27.8M-46.7%	$52.1M-41.3%	$88.7M+184.4%	$31.2M-35.8%	$48.6M+29.7%	$37.5M+113.3%	$17.6M-80.9%	$92.2M+34.4%	$68.6M+333.0%	-$29.4M-84.5%	-$16.0M
Retained Earnings	-$757.7M-3.6%	-$731.2M-5.8%	-$691.3M-4.3%	-$662.7M-3.6%	-$639.5M-13.0%	-$566.2M-82.3%	-$310.6M-180.7%	-$110.6M-86.9%	-$59.2M-96.5%	-$30.1M	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$23.6M-47.2%	$25.9M-54.1%	$30.2M-54.9%	$44.7M-48.4%	$56.4M-38.5%	$66.9M-31.5%	$76.2M+295.5%	$86.6M+247.2%
Current Assets	$23.5M-46.9%	$25.8M-53.0%	$30.0M-53.4%	$44.3M-47.1%	$54.9M-39.1%	$64.4M-32.9%	$73.5M+319.9%	$83.8M+264.9%
Cash & Equivalents	$22.9M+4.0%	$24.6M-12.7%	$24.0M+20.6%	$22.0M-25.5%	$28.2M+48.0%	$19.9M-34.9%	$16.3M+5.3%	$29.6M+43.5%
Short-Term Investments	$0-100.0%	$297K-98.7%	$5.0M-88.0%	$17.6M-63.7%	$22.1M-67.0%	$41.6M-33.6%	$53.9M	$48.5M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.5M-73.6%	$1.2M-89.9%	$2.4M-83.8%	$5.8M-50.5%	$12.3M+48.0%	$14.8M+65.6%	$12.7M+63.1%	$11.8M+53.2%
Current Liabilities	$1.5M-73.6%	$1.2M-89.9%	$2.4M-83.8%	$5.8M-50.3%	$12.3M+77.4%	$14.8M+96.6%	$12.7M+96.3%	$11.8M+84.4%
Non-Current Liabilities	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$25K-98.1%
Long-Term Debt	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$22.1M-43.3%	$24.6M-44.2%	$27.8M-46.7%	$38.9M-48.1%	$44.1M-47.1%	$52.1M-41.3%	$63.5M+452.3%	$74.9M+333.5%
Retained Earnings	-$764.2M-2.5%	-$761.2M-2.9%	-$757.7M-3.6%	-$745.5M-5.5%	-$739.8M-6.0%	-$731.2M-5.8%	-$719.1M-5.0%	-$707.0M-4.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

YARW Cash Flow Statement

YARW quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$33.1M+2.5%	-$34.0M-34.1%	-$25.3M+13.2%	-$29.2M+48.2%	-$56.4M+58.9%	-$137.1M-86.8%	-$73.4M-6.9%	-$68.7M-143.3%	-$28.2M-1146.0%	-$2.3M+45.9%	-$4.2M
Depreciation & Amortization	$23K+475.0%	$4K	$0-100.0%	$72K-33.9%	$109K-68.0%	$341K-2.6%	$350K+9.7%	$319K	N/A	N/A	N/A
Stock-Based Compensation	$2.3M-30.1%	$3.3M-0.1%	$3.3M-23.1%	$4.3M-46.8%	$8.1M-55.4%	$18.1M+269.8%	$4.9M-8.0%	$5.3M0.0%	$5.3M+828.4%	$573K+781.5%	$65K
Capital Expenditures	$0-100.0%	$117K	$0	N/A	$0-100.0%	$113K-89.3%	$1.1M+86.6%	$567K+2000.0%	$27K-12.9%	$31K	$0
Free Cash Flow	-$33.1M+2.8%	-$34.1M-34.5%	-$25.3M	N/A	-$56.4M+58.9%	-$137.2M-84.3%	-$74.5M-7.5%	-$69.2M-145.1%	-$28.2M-1130.4%	-$2.3M+45.1%	-$4.2M
Investing Cash Flow	$37.4M+59.9%	$23.4M+140.7%	-$57.4M-466.1%	$15.7M+1425.5%	$1.0M-98.8%	$89.1M+112.8%	$41.9M+456.2%	-$11.8M+22.1%	-$15.1M+59.8%	-$37.5M	$0
Financing Cash Flow	-$143K-1.4%	-$141K-100.2%	$82.4M+4884.5%	$1.7M-95.8%	$39.8M-35.6%	$61.8M+28.9%	$48.0M-48.1%	$92.4M+86.6%	$49.5M	$0-100.0%	$47.7M

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$2.0M+81.6%	-$4.1M+64.4%	N/A	-$10.8M-27.4%	-$11.5M-43.6%	-$9.0M-75.2%	-$8.5M-65.2%	-$8.5M+11.4%
Depreciation & Amortization	$6K-50.0%	$6K0.0%	N/A	$12K	$6K	N/A	N/A	$0
Stock-Based Compensation	$436K-17.6%	$474K-37.9%	N/A	$529K-40.2%	$763K-22.5%	N/A	$734K-14.9%	$885K+1.0%
Investing Cash Flow	$300K-93.6%	$4.7M-76.3%	N/A	$4.7M-75.4%	$19.8M+655.6%	$12.7M+120.4%	-$4.8M	$19.0M
Financing Cash Flow	-$14K+58.8%	-$15K+82.8%	N/A	-$34K-1600.0%	-$87K-1640.0%	-$132K-100.2%	-$2K+95.7%	-$2K+60.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

YARW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

YARW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Gross Margin	N/A	N/A	N/A	N/A	-259.6%	93.4%-6.6pp	100.0%0.0pp	100.0%	N/A	N/A	N/A
Operating Margin	-5219.1%	-8710.0%	-6900.5%	-7189.7%	-4179.5%	-1203.0%	-21641.8%	-2083.2%	-645.9%	-2126.4%	N/A
Net Margin	-4646.1%	-7950.9%	-6710.4%	-4865.8%	-7876.4%	-1217.4%	-21484.9%	-2062.9%	-634.6%	-2087.2%	N/A
Return on Equity	-95.4%-18.9pp	-76.5%-44.4pp	-32.1%+42.3pp	-74.4%+76.4pp	-150.8%+530.9pp	-681.6%-140.1pp	-541.5%-461.1pp	-80.5%-38.1pp	-42.4%	N/A	N/A
Return on Assets	-87.8%-28.3pp	-59.5%-30.4pp	-29.1%+27.8pp	-57.0%+52.4pp	-109.4%+163.3pp	-272.6%-155.4pp	-117.3%-64.3pp	-53.0%-9.5pp	-43.5%-10.0pp	-33.5%	N/A
Current Ratio	12.53+8.2x	4.35-8.4x	12.73+8.6x	4.10+0.7x	3.43-0.6x	4.01+1.4x	2.61-12.0x	14.62+6.4x	8.17+0.1x	8.08	N/A
Debt-to-Equity	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00-0.9x	0.88-1.0x	1.86+1.3x	0.52+0.3x	0.21	N/A	N/A
Asset Turnover	0.020.0x	0.010.0x	0.000.0x	0.010.0x	0.01-0.2x	0.22+0.2x	0.010.0x	0.030.0x	0.07+0.1x	0.02	N/A
FCF Margin	-5811.2%	-6804.2%	-5976.6%	N/A	-6054.5%	-653.5%	-16806.3%	-1925.8%	-616.5%	-340.6%	N/A

Metric	Q2'2610-Q	Q1'2610-K	Q4'2510-Q	Q2'2510-Q	Q1'2510-K	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Margin	-3197.9%	-4437.2%	N/A	-10930.4%	-4553.0%	-15202.4%	-10819.0%	-5250.5%
Net Margin	-3100.0%	-4168.6%	N/A	-8340.6%	-4262.9%	-14311.9%	-10047.1%	-4750.5%
Return on Equity	-13.6%+1.2pp	-14.5%+5.0pp	N/A	-14.8%-2.2pp	-19.5%-12.0pp	-23.1%-16.1pp	-19.1%+38.1pp	-12.6%+45.7pp
Return on Assets	-12.7%+0.1pp	-13.9%+1.4pp	N/A	-12.9%-2.0pp	-15.3%-8.4pp	-18.0%-11.6pp	-16.0%+18.2pp	-10.9%+29.4pp
Current Ratio	15.26+7.7x	20.86+16.4x	12.53+8.2x	7.60+0.5x	4.47-8.6x	4.35-8.4x	5.81+3.1x	7.13+3.5x
Debt-to-Equity	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Where Yarrow Bioscience, Inc. Ranks

Frequently Asked Questions

What is Yarrow Bioscience, Inc.'s annual revenue?

Yarrow Bioscience, Inc. (YARW) reported $570K in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Yarrow Bioscience, Inc.'s revenue growing?

Yarrow Bioscience, Inc. (YARW) revenue grew by 13.8% year-over-year, from $501K to $570K in fiscal year 2025.

Is Yarrow Bioscience, Inc. profitable?

No, Yarrow Bioscience, Inc. (YARW) reported a net income of -$26.5M in fiscal year 2025.

What is Yarrow Bioscience, Inc.'s EBITDA?

Yarrow Bioscience, Inc. (YARW) had EBITDA of -$29.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Yarrow Bioscience, Inc. have?

As of fiscal year 2025, Yarrow Bioscience, Inc. (YARW) had $24.0M in cash and equivalents against $0 in long-term debt.

What is Yarrow Bioscience, Inc.'s return on equity (ROE)?

Yarrow Bioscience, Inc. (YARW) has a return on equity of -95.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Yarrow Bioscience, Inc.'s free cash flow?

Yarrow Bioscience, Inc. (YARW) recorded an outflow of $33.1M in free cash flow during fiscal year 2025. This represents a 2.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Yarrow Bioscience, Inc.'s operating cash flow?

Yarrow Bioscience, Inc. (YARW) recorded an outflow of $33.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Yarrow Bioscience, Inc.'s total assets?

Yarrow Bioscience, Inc. (YARW) had $30.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Yarrow Bioscience, Inc.'s capital expenditures?

Yarrow Bioscience, Inc. (YARW) reported no capital expenditure during fiscal year 2025.

How much does Yarrow Bioscience, Inc. spend on research and development?

Yarrow Bioscience, Inc. (YARW) invested $19.2M in research and development during fiscal year 2025.

How many shares does Yarrow Bioscience, Inc. have outstanding?

Yarrow Bioscience, Inc. (YARW) had 33M shares outstanding as of fiscal year 2025.

What is Yarrow Bioscience, Inc.'s current ratio?

Yarrow Bioscience, Inc. (YARW) had a current ratio of 12.53 as of fiscal year 2025, which is generally considered healthy.

What is Yarrow Bioscience, Inc.'s debt-to-equity ratio?

Yarrow Bioscience, Inc. (YARW) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Yarrow Bioscience, Inc.'s return on assets (ROA)?

Yarrow Bioscience, Inc. (YARW) had a return on assets of -87.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Yarrow Bioscience, Inc.'s P/E ratio?

Yarrow Bioscience, Inc. (YARW) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $75.6M as of Sep 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Yarrow Bioscience, Inc.'s price-to-sales ratio?

Yarrow Bioscience, Inc. (YARW) trades at 133x sales, its market capitalization divided by revenue of $570K revenue, FY2025. The market capitalization is $75.6M as of Sep 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Yarrow Bioscience, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Yarrow Bioscience, Inc. (YARW) held $29.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $33.1M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Yarrow Bioscience, Inc.'s Altman Z-Score?

Yarrow Bioscience, Inc. (YARW) has an Altman Z-Score of -18.38, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Yarrow Bioscience, Inc.'s Piotroski F-Score?

Yarrow Bioscience, Inc. (YARW) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Yarrow Bioscience, Inc.'s earnings high quality?

Yarrow Bioscience, Inc. (YARW) reported a net loss of $26.5M while operations used $33.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.